tryptophan 2,3-dioxygenase

IDO TDO-IN-1 is an orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50s: 9.7 and 47 nM).

4-Phenylimidazole（4-Phl）用于研究细胞色素P450与蛋白质-配体相互作用，作为血红素配体在重组人色氨酸2,3-双加氧酶结晶过程中使用。

Indoximod (NLG-8189) 是一种具有口服具有活力的吲哚胺2,3-双加氧酶(IDO) 途径抑制剂。它在调节 mTOR 中充当 Trp 模拟物。它是一种可用于癌症研究的免疫代谢佐剂。

(S)-Indoximod (L-Abrine) 是一种吲哚胺-2,3-双加氧酶 (IDO) 抑制剂，可用于研究癌症。

LM10 是有效的色氨酸 2,3-双加氧酶的抑制剂。色氨酸 2,3-双加氧酶是一种无关的肝酶，它可通过犬尿氨酸途径降解色氨酸。它对研究癌症疾病具有潜在的研究价值。

(Rac)-Indoximod (1-Methyl-DL-tryptophan) is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO). Combined treatment with IFN-γ and (Rac)-Indoximod significantly suppresses the activity of α-SMA-expressing human cardiac myofibroblasts (hCMs) and promotes apoptosis by up-regulating the genes IRF-1, Fas, and FasL. Moreover, this co-treatment effectively improves cardiac fibrosis[1].

TDO-IN-1 是一种具有口服活性、有效性和选择性的色氨酸 2,3-双加氧酶 (TDO)抑制剂 ，对吲哚胺-2,3-双加氧酶 具有抑制作用。TDO-IN-1 具有抗肿瘤活性， 能够通过逆转肿瘤组织的局部免疫耐受来发挥作用。

NLG802 is an orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T lymphocytes, and causes a reduction in tumor-associated regulatory T cells (Tregs).